NEW-ONSET SEROPOSITIVE RHEUMATOID ARTHRITIS FOLLOWING SARS-COV-2 INFECTION AND AFTER COVID-19 VACCINATION

Shortly after the outbreak of atypical pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causative agent of COVID-19, reports have emerged regarding the presence of immunological phenomena and autoimmune rheumatic diseases, including new-onset seropositive rheumatoid arthritis (RA). Within less than 12 months of the epidemic, the Pfizer and Moderna mRNA vaccines demonstrated an efficacy of over 95%. With the time, side effects have also been documented. This study aimed to analyze patients who were diagnosed as RA following SARS-CoV-2 infection and after vaccination against COVID-19. The major characteristics of these patients are: polyarthritis predominantely of small joints; presence of anti-citrulline protein antibody in 94% and the combination with rheumatoid factor was of 86%; serum levels of inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) increased; the time interval between the viral infection or vaccination and the onset was 1 to 6 weeks; predominance in women, 77% of cases; six cases had pneumonia following SARS-CoV-2 vs 0 after COVID-19 vaccine; joint symptoms presented after the second dose in 10 (67%)/15 cases: two patients previously seronegative eventually developed seropositive RA; and there was a personal or family history of autoimmune diseases in 9 cases. Remission induction was achieved with methotrexate, with or without glucocorticoids, other disease-modifying antirheumatic drugs, and biological agents. Only 1 patient died of COVID-19. These findings show that in a limited number of cases, COVID-19 causes autoimmunity, possibly through molecular mimicry, adjuvants, or the activation of autoreactive T cells.

• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd, CO et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European ligue Against Rheumatism collaborative initiative. Arthritis Rheum, 2010; Sep; 62(9): 2569-81. 
• Roudier J, Balandraud N, Auger I. How RA associated HLA-DR molecules contribute to the development of antibodies to citrullinated proteins: the hapten carrier model. Front Immunol, 2022; June 13: 930112. 
• Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link? Arthritis Res Ther, 2006 Jan 16; 8(1): 204. 
• Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol, 2022; 20(5):    270-84. doi:10.1038/s41579-022-007-13-0
• Walls A.C, Park Y, Tortorici, MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020; 180: 281–292.
• Segal Y, Schoenfeld Y. Vaccine induced autoimunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol, 2018; 15: 586-594
• Dotan A, Muller S, Kanduc D, David P, Halpert G, Schoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmunity Rev., 2021; 20: 102792.
• Park IK, Lee EB, Winthrop KL. What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases. Ann Rheum Dis., 2024; 83: 687-695. 
• Bianchi A, Bottau P, Callmelli E, Caimmi S, Crisafulli G, Franceschini F et al. Hypersensitivity to polyethylene glycol in adults and children: An emerging challenge. Acta Biomedica, 2021 Nov 29; 92(Suppl 7): e2021519. 
• Ghang B, Kim S, Kim J. Autoimmune rheumatic disease after SAR-CoV-2 vaccination, J Med Virology, 2022: Sep 2: 10.10º2/
• Nune A, Durkowski, Pillay SS, Barman B, Elwell H, Bora K et al. New-onset rheumatic immune-mediated inflammatory diseases following SARS-CoV-2 vaccinations until May 2023. A systematic review. Vaccines, 2023; 11: 1571. 
• Chen CC, Chen CJ. New-onset inflammatory arthritis after COVID-19 vaccination: A systematic review. Int J Rheum Dis., 2023 Feb; 26(2): 267-277 
• Nielen MMJ, van Schaardenburg D, Reesink HW, van dae Stadt RJ, van der Horst-Bruinsman IE, Koning MHM et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum, 2004; feb; 50(2): 380-6.
• Kolfenbach JR, Deane KD, Derber LA, 0’Donnell CI, Gilliland WR, Edison JD et al.
• Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum, 2010; 9: 2633-9. 
• Aho, K, Paluoso T, Raunio V, PusKa P, Aromaa A, Salonen JT. When does rheumatoid disease start ?Arthritis Rheum., 1985; 28(5): 485-9. 
• Vahavi M, Ghazanfari T, Sepehrnia S. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease following COVID-19 infection. Int Immunopharmacol, 2022; 112: 109183.
• Fujimani R, von Herrath MG, Christen U, Lindsay WJ. Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease. Clin Microbiol Rev., 2006; 19: 80-94.